OWKIN Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:$74.1M
Industry:Biotech
Founded:2016
Lead Investor(s):F-Prime Capital, Eight Roads Ventures

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • OWKIN's estimated annual revenue is currently $24.8M per year.(?)
  • OWKIN received $Undisclosed in venture funding in March 2019.
  • OWKIN's estimated revenue per employee is $155,000
  • OWKIN's total funding is $74.1M.

Employee Data

  • OWKIN has 160 Employees.(?)
  • OWKIN grew their employee count by 22% last year.
  • OWKIN currently has 1 job openings.

OWKIN was co-founded in 2016 by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical hematology and Gilles Wainrib, PhD, a pioneer in the field of Artificial Intelligence in biology. OWKIN is an AI startup that uses machine learning to augment medical and biology research. Our proprietary platform, OWKIN Socrates, uses machine learning technology to integrate biomedical images, genomics and clinical data to discover biomarkers and mechanisms associated with diseases and treatment outcomes. Our team is international, multidisciplinary with incredible talent in machine learning, medicine and business. Our data scientists are among the best in the world, with several Kaggle Masters (top global 100), a DREAM Challenge top performer, and publications in ICML, NIPS and other top scientific journals. OWKIN develops scientific collaborations with top-tier medical institutions such as Mount Sinai, Inserm, Institut Curie and the Léon Bérard Center, and partners with leading pharmaceutical companies, including Amgen, Roche, and Ipsen. OWKIN has developed a state-of-the-art federated learning technology in healthcare to overcome the data sharing problem, building collective intelligence from distributed data at scale while preserving data privacy and security.

keywords:Biotechnology, Pharmaceuticals, Big Data, Artificial Intelligence